Study Summary
This trial will study the safety and effects of an IV infusion of a new medicine in healthy adults.
Treatment Effectiveness
Study Objectives
6 Primary · 17 Secondary · Reporting Duration: Day 1: 0-24 hours up to Day 113
Trial Safety
Trial Design
7 Treatment Groups
Part A, Cohort 1: E2025 Dose 1 or Placebo
1 of 7
Part A, Cohort 2: E2025 Dose 2 or Placebo
1 of 7
Part B Cohort 7: E2025 Dose 4
1 of 7
Part B, Cohort 6: E2025 Dose 3
1 of 7
Part A, Cohort 3: E2025 Dose 3 or Placebo
1 of 7
Part A, Cohort 4: E2025 Dose 4 or Placebo
1 of 7
Part B, Cohort 5: E2025 Dose 2
1 of 7
Experimental Treatment
41 Total Participants · 7 Treatment Groups
Primary Treatment: Part B Cohort 7: E2025 Dose 4 · Has Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 55 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is there an age limit for those wishing to participate in this experiment?
"Eligible participants for this medical trial must be aged 18 or over, but no more than 55 years old." - Anonymous Online Contributor
Are there any qualifications for participating in this research?
"In order to be accepted into this research, subjects should have no major medical conditions and must fall between 18-55 years of age. A total of 41 study volunteers are being sought after." - Anonymous Online Contributor
Are there still opportunities to partake in this investigation?
"According to clinicaltrials.gov, this research is no longer recruiting participants. Initially posted on February 6th 2023 and last updated on March 2nd 2023, the study has since closed its recruitment period yet 827 other studies are enrolling patients presently." - Anonymous Online Contributor
Is Part B, Cohort 6: E2025 Dose 3 likely to produce adverse effects in patients?
"Due to the fact that Part B, Cohort 6: E2025 Dose 3 is in its initial testing phase, our team at Power classified it as a 1 on the safety scale. This implies there is limited clinical data available for evaluating efficacy and security." - Anonymous Online Contributor